The Art of AMD: Appropriate Treatment Decision-Making in Patients With Macular Degeneration
Ophthalmology
Curriculum:
The Art of AMD
The Art of AMD
Credits:
1.5 AMA PRA Category 1 Credit(s) ™
1.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
August 25, 2013
August 25, 2013
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Opthalmologists, retina specialists
Relevant Terms:
Age-related Macular Degeneration, Macular Disease
Charles C. Wykoff, MD, PhD
Charles C. Wykoff, MD, PhD
Program Chair
Clinical Assistant Professor of Ophthalmology
Weill Cornell Medical College/The Methodist Hospital
Retina Consultants of Houston
Houston, TX
Bio
Dr. Charles Wykoff is Clinical Assistant Professor of Ophthalmology at Weill Cornell Medical College/The Methodist Hospital and a Physician Partner at Retina Consultants of Houston in Houston, Texas. He graduated Phi Beta Kappa from Massachusetts Institute of Technology. He received his doctor of philosophy in molecular biology from Oxford University in England and his medical degree from Harvard Medical School. Dr. Wykoff completed his ophthalmology residency and vitreoretinal fellowship at Bascom Palmer Eye Institute, where he was Chief Resident and was awarded a Heed Fellowship and the Ronald G. Michels Foundation Award, the nation’s highest honor for a retina surgery fellow. Dr. Wykoff's research interests pertain to angiogenesis and vitreoretinal surgery topics. He has published over 40 peer-reviewed scientific manuscripts and presented at numerous national meetings. He is a member of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology and the American Society of Retina Specialists.
Judy E. Kim, MD
Judy E. Kim, MD
Professor of Ophthalmology
Vitreoretinal Section
Medical College of Wisconsin
Milwaukee, WI
Bio
Judy E. Kim, MD, is a graduate of the University of Chicago, Johns Hopkins University School of Medicine, and Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program. She completed her ophthalmology residency training at Bascom Palmer Eye Institute and vitreoretinal fellowship at the Medical College of Wisconsin. Currently she is a Professor of Ophthalmology at the Medical College of Wisconsin. Dr. Kim has received numerous awards and honors, including being named in the “Best Doctors in America” annually since 2003 and is included in the US News & World Report Best Doctors list and Castle Connolly Top Doctors list. She has received the American Academy of Ophthalmology Achievement Award and the Senior Achievement Award, and the American Society of Retina Specialists Honor Award and Service Award. She is a Heed Foundation Fellow and has been selected to the Leadership Development Program of the American Academy of Ophthalmology. She has been elected to many regional and national leadership and committee positions and serves on the review boards of a number of peer-reviewed journals, including being invited to serve on the editorial board of JAMA Ophthalmology. Dr. Kim has authored over 130 publications, book chapters, and monographs related to age-related macular degeneration, diabetic retinopathy and other retinal diseases. She is a sought-after lecturer nationally and internationally. She is actively involved with a number of multicenter clinical trials, many as a site principal investigator, including Age-related Eye Disease 2 and Diabetic Retinopathy Clinical Research Network sponsored by the National Eye Institute. Her research interests include diabetic retinopathy, age-related macular degeneration, clinical trials, surgical retina, telemedicine and ocular imaging.
Garvin H. Davis, MD, MPH
Garvin H. Davis, MD, MPH
Clinical Assistant Professor of Vitreoretinal Diseases and Surgery
The Richard S. Ruiz, MD Department of Ophthalmology and Visual Science
The University of Texas Medical School at Houston
Houston, TX
Bio
Originally from Baker, Louisiana, Dr. Davis graduated from the Massachusetts Institute of Technology (MIT) where he majored in electrical engineering. During medical school at the Johns Hopkins School of Medicine, Dr. Davis spent an additional year earning a masters degree at the Johns Hopkins School of Public Health and completing a fellowship in Preventative Ophthalmology at the Wilmer Eye Institute. Dr. Davis then completed an ophthalmology residency at the Wills Eye Hospital in Philadelphia, Pennsylvania.
Following a two-year vitreoretinal fellowship at the Baylor College of Medicine, Dr. Davis joined the faculty of the University of Texas Medical Branch in Galveston, where he trained fellows and residents, and conducted research. After five years there, he transitioned to his current position as Clinical Assistant Professor and Director of the Retina Service for The Richard S. Ruiz, MD Department of Ophthalmology and Visual Science at the University of Texas at Houston Medical School.
Dr. Davis has published articles and book chapters, and participated in retinal clinical trials and research networks. His research interests include public health ophthalmology, health services research, retinal prosthesis, and nanotechnology.
Following a two-year vitreoretinal fellowship at the Baylor College of Medicine, Dr. Davis joined the faculty of the University of Texas Medical Branch in Galveston, where he trained fellows and residents, and conducted research. After five years there, he transitioned to his current position as Clinical Assistant Professor and Director of the Retina Service for The Richard S. Ruiz, MD Department of Ophthalmology and Visual Science at the University of Texas at Houston Medical School.
Dr. Davis has published articles and book chapters, and participated in retinal clinical trials and research networks. His research interests include public health ophthalmology, health services research, retinal prosthesis, and nanotechnology.
| 1. | Describe the most recent efficacy data for various AMD treatments | 2. | Compare and contrast molecular structure of the different agents used to treat AMD and the potential implications for safety |
| 3. | Integrate advances in the understanding of efficacy, dosing options, safety, and molecular structure of agents used to treat AMD into overall treatment plans for AMD as appropriate |
| 1. | Describe the most recent efficacy data for various AMD treatments |
| 2. | Compare and contrast molecular structure of the different agents used to treat AMD and the potential implications for safety |
| 3. | Integrate advances in the understanding of efficacy, dosing options, safety, and molecular structure of agents used to treat AMD into overall treatment plans for AMD as appropriate |
STATEMENT OF SUPPORT
This activity is jointly sponsored by RMEI, LLC and Postgraduate Institute for Medicine, and is supported by an educational grant from Genentech.
CONTINUING EDUCATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
FEE INFORMATION
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Charles C. Wykoff, MD, PhD, has affiliations with Thrombogenics, Alimeca, Bayer, and Synergetics (Consultant); and Regeneron and Genentech (Speakers' Bureau).
- Judy E. Kim, MD, has affiliations with Thrombogenics (Consultant).
- Garvin H. Davis, MD, MPH, has no affiliations with commercial interests to disclose.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
RMEI, LLC
- Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
- Cynthia M. Kunzer, CMP, has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 18.0+ for Windows, Mac OS, or Linux Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux Safari 4.0+ for Mac OSX 10.5 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
